Savara Inc. (FRA:YB4P)

Germany flag Germany · Delayed Price · Currency is EUR
5.05
-0.05 (-0.98%)
At close: Jan 16, 2026
98.82%
Market Cap1.10B +74.4%
Revenue (ttm)n/a
Net Income-98.56M
EPS-0.46
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume10
Open4.98
Previous Close5.10
Day's Range4.98 - 5.05
52-Week Range1.66 - 5.90
Betan/a
RSI38.18
Earnings DateMar 30, 2026

About Savara

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
Founded 2007
Employees 59
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol YB4P
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements